Porteus M H, Narkool P, Neuberg D, Guthrie K, Breslow N, Green D M, Diller L
Dana-Farber Cancer Institute, Department of Pediatrics and Department of Biostatistics, Harvard Medical School, and Children's Hospital, Boston, MA 02115, USA.
J Clin Oncol. 2000 May;18(10):2026-31. doi: 10.1200/JCO.2000.18.10.2026.
Children with Beckwith-Wiedemann syndrome (BWS) are at increased risk for developing Wilms' tumor (WT). We reviewed the National Wilms Tumor Study Group (NWTSG) records to assess clinical characteristics and outcome of patients with WT and BWS.
In the NWTSG, treating clinicians were asked to report, for each enrolled patient, whether the patient had BWS. Between 1980 and 1995, 4,669 patients were treated on two consecutive NWTSG protocols (NWTS 3 and NWTS 4). We retrospectively reviewed the clinical characteristics and treatment outcomes of BWS patients compared with patients with WT without BWS.
Fifty-three children enrolled onto NWTS 3 and 4 were reported to have BWS. BWS patients were more likely to present with lower-stage tumors (P =.0001), with more than half (27 of 53) presenting with stage I disease. The overall treatment outcomes for the BWS patients were nearly identical to those without BWS, with overall survival at 4 years from diagnosis at 89% and 90%, respectively. Overall, 21% of the patients with BWS had bilateral disease, either at diagnosis (nine of 53) or as metachronous contralateral recurrence (two of 53). BWS patients enrolled onto NWTS 4 had smaller tumors than those enrolled onto NWTS 3 (P =.02), a trend not seen in the non-BWS patients.
Like children without BWS, children with BWS and WT have an excellent prognosis with modern treatment regimens. There is a high risk of bilateral disease, and increasingly smaller tumors are being detected. This suggests that a national trial assessing the role of ultrasound screening followed by nephron-sparing surgery for some patients may be appropriate.
患有贝克威思-维德曼综合征(BWS)的儿童患肾母细胞瘤(WT)的风险增加。我们回顾了国家肾母细胞瘤研究组(NWTSG)的记录,以评估WT和BWS患者的临床特征及预后。
在NWTSG中,要求治疗医生报告每例入组患者是否患有BWS。1980年至1995年期间,4669例患者按照NWTSG的两个连续方案(NWTS 3和NWTS 4)接受治疗。我们回顾性分析了BWS患者与无BWS的WT患者的临床特征和治疗结果。
据报告,53例儿童入组NWTS 3和4时患有BWS。BWS患者更有可能表现为低分期肿瘤(P = 0.0001),超过一半(53例中的27例)表现为I期疾病。BWS患者的总体治疗结果与无BWS的患者几乎相同,诊断后4年的总生存率分别为89%和90%。总体而言,21%的BWS患者患有双侧疾病,要么在诊断时(53例中的9例),要么作为异时性对侧复发(53例中的2例)。入组NWTS 4的BWS患者的肿瘤比入组NWTS 3的患者小(P = 0.02),非BWS患者未观察到这种趋势。
与无BWS的儿童一样,患有BWS和WT的儿童采用现代治疗方案预后良好。双侧疾病风险高,且检测到的肿瘤越来越小。这表明,开展一项全国性试验,评估超声筛查并随后对部分患者进行保留肾单位手术的作用可能是合适的。